Cost-effectiveness analysis of interferon as adjuvant therapy in high-risk melanoma patients in Spain (Q61917277)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11094308%20AND%20SRC:MED&resulttype=core&format=json

2 November 2019

title

Cost-effectiveness analysis of interferon as adjuvant therapy in high-risk melanoma patients in Spain (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11094308%20AND%20SRC:MED&resulttype=core&format=json

Jose Luis Gonzalez Larriba

2 November 2019

author

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11094308%20AND%20SRC:MED&resulttype=core&format=json

2 November 2019

Eduardo Díaz-Rubio

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11094308%20AND%20SRC:MED&resulttype=core&format=json

2 November 2019

author name string

S Serrano

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11094308%20AND%20SRC:MED&resulttype=core&format=json

2 November 2019

M Alvarez-Mon

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11094308%20AND%20SRC:MED&resulttype=core&format=json

2 November 2019

F Camacho

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11094308%20AND%20SRC:MED&resulttype=core&format=json

2 November 2019

L Fosbrook

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11094308%20AND%20SRC:MED&resulttype=core&format=json

2 November 2019

V Guillem

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11094308%20AND%20SRC:MED&resulttype=core&format=json

2 November 2019

J Toribio

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11094308%20AND%20SRC:MED&resulttype=core&format=json

2 November 2019

M A Casado

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11094308%20AND%20SRC:MED&resulttype=core&format=json

2 November 2019

J L Díaz-Pérez

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11094308%20AND%20SRC:MED&resulttype=core&format=json

2 November 2019

J J López-López

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11094308%20AND%20SRC:MED&resulttype=core&format=json

2 November 2019

J A Moreno-Nogueira

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11094308%20AND%20SRC:MED&resulttype=core&format=json

2 November 2019

publication date

1 December 2000

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11094308%20AND%20SRC:MED&resulttype=core&format=json

European Journal of Cancer

2 November 2019

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11094308%20AND%20SRC:MED&resulttype=core&format=json

2 November 2019

volume

36

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11094308%20AND%20SRC:MED&resulttype=core&format=json

2 November 2019

issue

18

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11094308%20AND%20SRC:MED&resulttype=core&format=json

2 November 2019

page(s)

2344-2352

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11094308%20AND%20SRC:MED&resulttype=core&format=json

2 November 2019

cites work

Cancer statistics, 1997.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2800%2900304-X

7 January 2021

Finally, a successful adjuvant therapy for high-risk melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2800%2900304-X

7 January 2021

Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2800%2900304-X

7 January 2021

An estimate of the annual direct cost of treating cutaneous melanoma.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2800%2900304-X

7 January 2021

Guidelines for authors and peer reviewers of economic submissions to the BMJ. The BMJ Economic Evaluation Working Party

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2800%2900304-X

7 January 2021

Economic analysis of adjuvant interferon alfa-2b in high-risk melanoma based on projections from Eastern Cooperative Oncology Group 1684.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2800%2900304-X

7 January 2021

The annual risk of melanoma progression. Implications for the concept of cure

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2800%2900304-X

7 January 2021

Late recurrence of malignant melanoma. Analysis of 168 patients.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2800%2900304-X

7 January 2021

A comparative cost analysis of terminal cancer care in home hospice patients and controls

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2800%2900304-X

7 January 2021

A retrospective cost-effectiveness analysis of interferon as adjuvant therapy in high-risk resected cutaneous melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2800%2900304-X

7 January 2021

Economic analysis of health technologies and programmes. A Spanish proposal for methodological standardisation

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2800%2900304-X

7 January 2021

Economic analyses of benefit from interferon-alpha 2B in high-risk melanoma: trade-offs between completeness, simplicity and clarity

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2800%2900304-X

7 January 2021

Discounting and health benefits

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2800%2900304-X

7 January 2021

Cost-effectiveness analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2800%2900304-X

7 January 2021

Screening for melanoma by primary health care physicians: a cost-effectiveness analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2800%2900304-X

7 January 2021

Adjuvant therapy for cutaneous malignant melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2800%2900304-X

7 January 2021

Adjuvant therapy for melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2800%2900304-X

7 January 2021

Results of adjuvant interferon study in WHO melanoma programme

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2800%2900304-X

7 January 2021

Randomized, surgical adjuvant clinical trial of recombinant interferon alfa-2a in selected patients with malignant melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2800%2900304-X

7 January 2021

Randomised trial of interferon alpha-2a as adjuvant therapy in resected primary melanoma thicker than 1.5 mm without clinically detectable node metastases. French Cooperative Group on Melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2800%2900304-X

7 January 2021

Quality-of-life-adjusted survival analysis of interferon alfa-2b adjuvant treatment of high-risk resected cutaneous melanoma: an Eastern Cooperative Oncology Group study

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2800%2900304-X

7 January 2021

10.1016/S0959-8049(00)00304-X

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11094308%20AND%20SRC:MED&resulttype=core&format=json

2 November 2019

1 reference